Abstract
Recent basic research has shown that Long non-coding RNA PSMB8-AS1 can promote the progression of atherosclerosis. The primary aim of this study was to investigate whether serum PSMB8-AS1 levels can predict acute coronary syndrome (ACS) in patients with chest pain. A total of 109 chest pain patients excluded from coronary artery disease (CAD), and 172 ACS patients, were enrolled from our center. Logistic regression analysis was performed to construct predictive models using traditional cardiovascular risk factors and then combined with PSMB8-AS1. Receiver operating characteristic (ROC) analysis was used to evaluate the predictive ability of these models. Additionally, an external validation cohort, including 15 non-CAD chest pain patients and 26 ACS patients, was used for validation. Serum PSMB8-AS1 levels were significantly higher in ACS patients compared to non-CAD patients. After adjusting for traditional risk factors, PSMB8-AS1 was independently associated with ACS (Adjusted OR = 3.826, 95% CI 2.321-6.305, P < 0.001). ROC analysis indicated that the model incorporating PSMB8-AS1 significantly improved the predictive ability for ACS compared to the traditional risk factor-based model (AUC: 0.785 vs 0.705, DeLong test P = 0.0036). Importantly, these findings were validated in the external cohort. PSMB8-AS1 could serve as a novel biomarker for predicting acute coronary syndrome.